ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
ACELYRIN (Nasdaq: SLRN) will report its third quarter 2024 financial results and provide a corporate update on November 13, 2024, at 4:30 p.m. ET. The company focuses on developing transformative medicines in immunology. A live webcast of the conference call will be available on ACELYRIN's website under Events & Presentations, with a replay accessible for 90 days.
ACELYRIN (Nasdaq: SLRN) comunicherà i suoi risultati finanziari per il terzo trimestre del 2024 e fornirà un aggiornamento aziendale il 13 novembre 2024, alle 16:30 ET. L'azienda si concentra sullo sviluppo di farmaci trasformativi in immunologia. Una diretta web della conferenza sarà disponibile sul sito di ACELYRIN sotto la sezione Eventi e Presentazioni, con una registrazione accessibile per 90 giorni.
ACELYRIN (Nasdaq: SLRN) dará a conocer sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización corporativa el 13 de noviembre de 2024 a las 4:30 p.m. ET. La compañía se enfoca en el desarrollo de medicamentos transformadores en inmunología. Se podrá ver una transmisión en vivo de la llamada de conferencia en el sitio web de ACELYRIN, en la sección de Eventos y Presentaciones, con una repetición accesible durante 90 días.
ACELYRIN (Nasdaq: SLRN)은 2024년 3분기 재무 실적을 발표하고 2024년 11월 13일 오후 4시 30분 ET에 기업 업데이트를 제공할 예정입니다. 이 회사는 면역학 분야의 혁신적인 의약품 개발에 집중하고 있습니다. ACELYRIN의 웹사이트에서 이벤트 및 프레젠테이션 섹션 아래에서 컨퍼런스 콜의 생중계를 시청할 수 있으며, 90일 동안 다시 볼 수 있는 재생도 제공됩니다.
ACELYRIN (Nasdaq: SLRN) annoncera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour de l'entreprise le 13 novembre 2024 à 16h30 ET. L'entreprise se concentre sur le développement de médicaments transformateurs en immunologie. Un webinaire en direct de l'appel de conférence sera disponible sur le site d'ACELYRIN dans la section Événements et Présentations, avec un accès à la rediffusion pendant 90 jours.
ACELYRIN (Nasdaq: SLRN) wird am 13. November 2024 um 16:30 Uhr ET die Finanzergebnisse für das dritte Quartal 2024 bekannt geben und ein Unternehmensupdate bereitstellen. Das Unternehmen konzentriert sich auf die Entwicklung von transformierenden Medikamenten im Bereich Immunologie. Eine Live-Webcast der Telefonkonferenz wird auf der Website von ACELYRIN unter Veranstaltungen und Präsentationen verfügbar sein, mit einer Zugänglichkeit zur Wiederholung für 90 Tage.
- None.
- None.
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates.
A live webcast of the conference call will be available on the Company’s website under Events & Presentations. A replay of the webcast will be available on the Company’s website for 90 days.
About ACELYRIN
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN’s lead program, lonigutamab, is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease.
For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking Statements
Some statements in this press release are, or may be considered, forward-looking statements, including statements regarding ACELYRIN’s progress, business plans and clinical trials, as well as the potential future benefits of our product candidates. While ACELYRIN, INC. considers any projections to be based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated in such forward-looking statements.
ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com
FAQ
When will ACELYRIN (SLRN) report its third quarter 2024 financial results?
How can I access the ACELYRIN (SLRN) third quarter 2024 financial results conference call?
Will a replay of ACELYRIN's (SLRN) third quarter 2024 financial results webcast be available?
